Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
For patients with stage III Lung Cancer, We propose one cycle chemotherapy using Abraxane and
Carboplatin, followed by pulsed low-dose sensitizing Abraxane chemotherapy and daily
Radiation. This will be followed by more hi-dose chemotherapy. We anticipate this regimen to
target early distant microscopic spread by using one cycle of chemotherapy prior to
radiation, and to achieve control of the disease in the lung by combining pulsed low-dose
sensitizing Abraxane, with radiation.